MedTrace Logo

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

NCT00791752 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-06-16

No results posted yet for this study

Summary

The primary aim of this study is to investigate the safety and tolerabilty of AZD4017 when given as single oral ascending doses to healthy volunters. This will be done by comparing the effect of AZD4017 to placebo. The study will aslo investigate the absorption, distrubution and disappearance of AZD4017 in the body. Information about plasma concentrations of AZD4017 vs time after dose intake will also be collected. The future indication for AZD4017 is planned to be Type 2 Diabetes Mellitus.

Conditions

  • Healthy

Interventions

DRUG

AZD4017

ascending single doses (start dose 2 mg), oral suspension

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Marianne Hartford, MD PhD · Sahlgrenska University Sweden

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Completion
2009-03-31

Countries

  • Sweden

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00791752 on ClinicalTrials.gov